SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced four presentations at upcoming healthcare events. The presentations will highlight work related to the two product candidates that ViaCyte is actively developing.
Details of the presentations are as follows:
Event: | BioJapan 2016 | |
Speaker: | Dr. Mark Zimmerman, Vice President, Strategy & Business Development | |
Presentation: | Front-line R&D of Regenerative Medicine Products | |
Date/Time: | October 14, 3:00 pm JST | |
Location: | Annex Hall F205/F206, Pacifico Yokohama | |
Yokohama, Kanagawa Prefecture, Japan | ||
Event: | International Stem Cell Initiative: The Origins and Implications of Pluripotent Stem Cell Genetic and Epigenetic Instability at Jackson Labs | |
Speaker: | Dr. Allan Robins, Senior Vice President, Science & Technology | |
Date/Time: | October 15, 8:00 am EDT | |
Location: | Jackson Labs, Bar Harbor, Maine | |
Event: | 2016 BIO Investor Forum | |
Speaker: | Dr. Paul Laikind, President & CEO | |
Date/Time: | October 18, 9:30 am PDT | |
Location: | Elizabethan D, Westin St. Francis, San Francisco, California | |
Event: | International Conference on Stem Cell Engineering | |
Speaker: | Dr. Kevin D’Amour, Vice President, Research, & Chief Scientific Officer | |
Date/Time: | October 25, 2:45 pm EDT | |
Location: | Toronto Marriott Bloor Yorkville, Ontario, Canada |
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
About ViaCyte
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in durable and retrievable delivery devices. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte has two products in development. The PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired hypoglycemia awareness. The PEC-Encap (also known as VC-01) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte here: www.twitter.com/viacyte and www.facebook.com/viacyte.
Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viacyte-to-present-at-healthcare-events-in-october-300342411.html
SOURCE ViaCyte, Inc.
